In another study of 370 participants using different drugs to treat IBD, the use of anti-TNF and tofacitinib was associated with lower concentrations of antibodies compared with the general population, unlike what was observed with other therapeutic regimens [30]. Here, TNF is linked to inflammatory bowel disease.